Bullous pyoderma gangrenosum as a predictor of hematological malignancies

Vacas, Aldana Soledad; Bollea-Garlatti, M.L.; Torre, Ana Clara; Galimberti, Ricardo

doi:10.1590/abd1806-4841.20187031

Cited by 12 publications

(6 citation statements)

References 6 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other clinical subtypes of PG may be associated with underlying systemic diseases at different rates than classical PG. For example, it has been reported that 70% of Bullous PG cases develop alongside hematologic diseases, such as myelogenous leukemia, lymphoma, monoclonal gammopathy, and myelodysplastic syndromes [ 43 , 44 ].…”

Section: Pyoderma Gangrenosummentioning

confidence: 99%

“…Evaluation should begin with a thorough medical history to the assessment of risk factors and associated diseases including the history of IBD, autoimmune arthritis, and/or malignancy. Temporal evaluation relating to underlying and triggering events should be considered, although initial PG diagnosis has been shown to both precede, coincide with, and/or follow underlying systemic disease activity [ 44 ].…”

Section: Pyoderma Gangrenosummentioning

confidence: 99%

See 1 more Smart Citation

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

et al. 2022

View full text Add to dashboard Cite

Purpose of Review Neutrophilic dermatoses are a heterogeneous group of disorders with significant overlap in associated conditions, clinical presentation, and histopathologic features. This review provides a structural overview of neutrophilic dermatoses that may present in the inpatient setting along with diagnostic work-up and management strategies. Recent Findings Sweet’s syndrome has been found in patients with coronavirus disease 2019 (COVID-19). Pyoderma gangrenosum (PG) has been shown to be equally associated with ulcerative colitis and Crohn’s disease. A clinical trial shows that cyclosporine is equally effective as prednisone in treating PG. Neutrophilic eccrine hidradenitis has been found in the setting of newer antineoplastic medications, such as BRAF inhibitors, as well as in the setting of malignancy without chemotherapy exposure. Summary Neutrophilic dermatoses are a rare and complex group of dermatoses with varying and overlapping clinical presentations. Physicians should be aware of the growing list of associated diseases in order to build a better differential diagnosis or to potentially investigate for co-existing disease.

show abstract

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a systematic review published in 2015 including 823 cases of PG, HMs have been found to be associated with this condition in 12.5% of patients, following inflammatory bowel diseases ( n = 537; 65.2%) and polyarthritis ( n = 133; 16.1%) [ 66 ]. Haematological malignancies associated with PG, which are a major cause of death in this disease [ 41 , 67 ], are mainly represented by acute and chronic myeloid leukaemia [ 68 , 69 ], myelodysplastic syndrome [ 70 ], multiple myeloma [ 71 ], monoclonal gammopathy of undetermined significance [ 72 ] and lymphoma [ 73 ]. Although IgG isotype gammopathies are overall more frequent, most monoclonal gammopathies associated with PG are of the IgA isotype [ 47 , 74 ].…”

Section: Neutrophilic Dermatosesmentioning

confidence: 99%

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological malignancies, run a benign clinical course but portend a significant negative impairment on a patient's quality of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haematological malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date overview on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, discussing new pathogenic advances and therapeutic options on the horizon.

show abstract

“…IgG gammopathies are more frequent; however, the ones associated with PG are immunoglobulin A (IgA) [ 16 ]. The association between HM and PG has been observed as a cause of death [ 16 , 21 ], mainly in AML, CML, MDS, MM, MGUS, and lymphoma.…”

Section: Reviewmentioning

confidence: 99%

Immune-Mediated Cutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies: Skin as a Mirror of Hematologic Neoplasms

Álvarez-Payares¹,

Molina²,

Gallo³

et al. 2021

Cureus

View full text Add to dashboard Cite

Malignant neoplasms may present as paraneoplastic syndromes with mucocutaneous manifestations, which may or may not be chronologically associated. The pathophysiological mechanism is complex and not completely understood; therefore, definitive diagnosis may be achieved with a precise differential diagnosis based on the morphology of skin lesions, clinical picture, and histological pattern. The complexities, and low frequency, make the therapeutic approach quite challenging; consequently, the cornerstone of therapy is the eradication of the underlying neoplasms. Corticosteroids are the therapy of choice for most of these immune-mediated manifestations, but for the most part, the successful resolution requires the eradication of the underlying malignancy.

show abstract

Bullous pyoderma gangrenosum as a predictor of hematological malignancies

Cited by 12 publications

References 6 publications

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

Immune-Mediated Cutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies: Skin as a Mirror of Hematologic Neoplasms

Contact Info

Product

Resources

About